INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)
(Not for submission under 37 CFR 1.99)

Application Number		10584740
Filing Date		2006-06-26
First Named Inventor Hikan		u Matsuda
Art Unit		3738
Examiner Name	TBA	
Attorney Docket Numb	er	49288 2900

					U.S.	PATENTS			Remove	1	
Examiner Initial*	Cite No Patent Number Kind Code Issue Date Name of Patentee or Application of cited Document					Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1	5618312		1997-04	1-08	Yui, et al.					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion		Name of Patentee or Applicant Relevant		s,Columns,Lines where ant Passages or Relevant is Appear		
	1	20030072741		2003-04	I-17	Berglund, et al.					
If you wis	h to a	dd additional U.S. Publi				information p		d button	Add		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	,	Kind Code ⁴	Publication	Name of Patente Applicant of cited Document	or	Pages,Co where Re	olumns,Lines levant or Relevant	
	1	WO 2005/009498	wo			2005-02-03	Saimed Life System	ns, Inc.			С
	2	EP1452150A1	EP			2004-09-01	Organogenesis Inc				Г
	3	WO 01/80921	wo			2001-11-01	Emory University				С

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10584740		
Filing Date		2006-06-26		
First Named Inventor	Hikaru Matsuda			
Art Unit		3738		
Examiner Name TBA				
Attorney Docket Number		49288.2900		

If you wisl	h to a	d additional Foreign Patent Document citation information please click the Add button Add	Т						
		NON-PATENT LITERATURE DOCUMENTS Remove	-						
Examiner Initials*	Cite No	e name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), etc, (it) and/or country where published.							
	1	UCHMURA, E., et al. "Novel method of preparing acellular cardiovascular grafts by decellularization with poly (ethylene glycol)", Journal of Biomedical materials Research, Wiley, New York, NY, vol. 67A, no. 3, (2003-12-01), pgs. 954-957							
	2	UEDA, Y., et al.: "Development of acellular tissue for cardiovascular applications", international Journal of Artificial Organs, Milan, IT, vol. 23, no. 7, July 2003, pg. 598							
	3	Copy of Supplemental European Search Report dated 02/09/2007							
If you wis	h to a	id additional non-patent literature document citation information please click the Add button Add	_						
		EXAMINER SIGNATURE	Π						
Examiner	Signa	ture Date Considered	_						
		tital if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a conformance and not considered. Include copy of this form with next communication to applicant.							

See first Occese of UBPTO Potent Documents at year, UBPTO BOLD, OR YERPE 9010.4. Exter office that issued the occurrent, by the ho-letter code (WPDO Bold of See 1), and the property of the p

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10584740
Filing Date		2006-06-26
First Named Inventor	Hikan	Matsuda
Art Unit		3738
Examiner Name	TBA	
Attorney Docket Number		49288.2900

CERTIFICATION STATEMENT

Please see	37	CFR	1 97	and	1 98 h	n make the	appropriate	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sea 97 CFR 137(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 177(vi).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Howard I Sobelman

_ ...

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

39038

Signature	/Howard I Sobelman/	Date (YYYY-MM-DD)	2007-03-07

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIN OTS CRID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.